RE:Gilles "Gilles is usless as a CEO full stop."
He's only developed a base business that has grown at a double-digit growth rate for a decade as it moved out of a business incubator into its own state-of-the-art plant. CZO's base business has been praised by a $20 billion market cap company(Symrise) recently for the long standing product development partnership it has with Symrise.
“Ceapro and Symrise have a long-standing relationship in product development that has benefitted both companies over the years,” said Joern Andreas, President Cosmetic Ingredients Division, Symrise AG. “We see great value in this partnership and are very pleased to have secured this agreement, which will continue to pave the way for future developments that I believe will benefit both companies in creating value.”
Under Gilles leadership the first pharma-grade beta glucan pill was created uning novel PGX technology and brought to a clinical trial. You yourself thought this should be tested in trials and you are not alone as it is well supported in the scientific literature. There are no guarentees in science. The risk/reward was there, however; and CZO has better immediate priorities.
Gilles has subsequently developed the pharma-grade aventhramide pill and brought it to clinical trial approval. The trial is set to commence and has now been approved by the Montreal Heart Institute's Ethics Board for initiation. Avenanthramide is the reason Gilles joined the company and now it is about to be tested in trials under Dr. Jean-Claude Tardif who is a leader in inflammation and heart disease.
The fibrosis drug is before a Phase I clinical tral decision in the summer wich is only a few months away now. Macrophages are cited in the scientific literature as an important target for future treatments and CZO has a technology that scientists at McMaster are excited about. Dr. Ask has become a leading scientist at the second largest pharma in the world(Novartis). Dr. Ask and Dr. Kolb worked on Avalyn's technology which raised C$80 million preclinically and has had success in trials.
PGX continues to advance with blowout bioavailability results with new carriers that appear to address the needs of industry as infomed by discussions with industry and talks concenring the prototype PGX-YBG. The Canadain government continues to support the science.
Ronnie Miller has joined CZO from the largest biotech company in the world. He became a Board member and than Chairman. He has praised the pieces Gilles has brought together and supported its long term plans.
Out of the 300 posts that you have on Stockhouse and CZO not one, that is not even 0.00333% of them, have ever went into a deep dive concenrning the a single pipeline pipeline asset. You just aren't interested in what CZO is doing. You've admited that you don't even listen to the presentations. You are probably better suited to an investment that you are interested in as oppsed to this comapny.
This is a development stage company. Development stage assets are very hard to forecast when it comes to timelines. What CZO is doing has never been done before in human history. Much in the development stage is never successful. The failure rates are high. CZO has a base business to support multiple pipeline opportunities. Clinical trials can be much clearer in terms of a timeline than trying to invent something. With potentially two clinical trials shortly CZO has reached an important potential milestone. Symrise sees a path to future developments that can add value as it said int he news release. There are also other opportuntiies CZO is developing.